2025
- FHI (2025): Pasienters erfaringer med behandling av langvarig utmattelse av uklar årsak
Folkehelseinstituttet – oppsummerer forskning og erfaringer fra behandlingstilbud for langvarig utmattelse uten klar medisinsk årsak.
2024
- Six-year follow-up of participants in two clinical trials of rituximab or cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
- Assessing Functional Capacity in Myalgic Encephalopathy/Chronic Fatigue Syndrome: A Patient-Informed Questionnaire
2023
- Understanding, diagnosing, and treating Myalgic Encephalomyelitis/Chronic Fatigue Syndrome – State of the art: Report of the 2nd international meeting at the Charité Fatigue Center
- Corrigendum: Cognitive behavioral therapy improves physical function and fatigue in mild and moderate chronic fatigue syndrome…
- Endothelial dysfunction in ME/CFS patients
- Gastric dysmotility and gastrointestinal symptoms in ME/CFS
- Severe and Very Severe ME/CFS in Norway: Symptom Burden and Access to Care
2022
- Activity monitoring and patient-reported outcome measures in ME/CFS patients
- Genetic association study in ME/CFS identifies several potential risk loci
- No replication of previously reported association with genetic variants in the TRA locus for ME/CFS
2021
- Pathomechanisms and possible interventions in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)
- A map of metabolic phenotypes in patients with myalgic encephalomyelitis/chronic fatigue syndrome
- Reduced Endothelial Function in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome – Results From Open-Label Cyclophosphamide Intervention Study
- Fine mapping of the major histocompatibility complex (MHC) in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) suggests involvement of both HLA class I and class II loci
- Cognitive Behavioral Therapy Improves Physical Function and Fatigue in Mild and Moderate Chronic Fatigue Syndrome: A Consecutive Randomized Controlled Trial of Standard and Short Interventions
2020
- Human Leukocyte Antigen alleles associated with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
- Intravenous Cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. An Open-Label Phase II Study
2019
- Immunosignature Analysis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
- Rituximab Serum Concentrations and Anti-Rituximab Antibodies During B-Cell Depletion Therapy for Myalgic Encephalopathy/Chronic Fatigue Syndrome
- B-Lymphocyte Depletion in Patients With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial
- Searching for Serum Antibodies to Neuronal Proteins in Patients With Myalgic Encephalopathy/Chronic Fatigue Syndrome
2018
- Kronisk utmattelsessyndrom og pyruvat dehydrogenasefunksjon
- Consolidative Radiotherapy to Residual Masses After Chemotherapy Is Associated With Improved Outcome in Diffuse Large B-Cell Lymphoma. A Retrospective, Population-Based Study
2016
- Metabolic profiling indicates impaired pyruvate dehydrogenase function in myalgic encephalopathy/chronic fatigue syndrome
- Serum BAFF and APRIL Levels, T-Lymphocyte Subsets, and Immunoglobulins after B-Cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Myalgic Encephalopathy/Chronic Fatigue Syndrome
2015
2009
Sist oppdatert 18.02.2026